Study of High Risk Non Invasive Prenatal Test Population
NCT ID: NCT04737070
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2021-02-01
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to french guidelines, these patients needs to have a invasive test (such as amniocentesis) but some patients prefer to have a Non Invasive Prenatal Test, with a potential lack of information.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Screening of Fetal Trisomy 21 by Digital PCR
NCT03687866
Trisomy of Chromosome 21 Diagnosis by High Output Sequencing
NCT01118507
T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients
NCT02424474
Non Invasive Prenatal Testing of Down Syndrome
NCT02127515
High Risk Multiple Gestation Study
NCT02278874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prenatal test for Trisomy 21 screening
prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthieu DAP
medical doctor (MD)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020PI310
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.